Cohance Lifesciences plunged to a 52-week low after weak Q1 results, with adjusted profit falling 25% YoY to ₹62.9 crore. Analyst Akhilesh Jat flagged a breakdown below ₹930, turning bias negative unless the stock reclaims that level. Retail sentiment on Stocktwits is 'extremely bearish.' Support lies at ₹888, while resistance is seen at ₹930-950.